In adults with type 2 diabetes on insulin glargine, adding tirzepatide 5, 10 or 15 mg once weekly lowered HbA1c at week 40 more than adding placebo (change from baseline -2.40% with 10 mg and -2.34% with 15 mg versus -0.86% with placebo; significant for every dose).
In plain wordsIn adults with type 2 diabetes using insulin glargine, adding tirzepatide lowered long-term blood sugar (HbA1c) more than adding placebo.
- Peptide
- Tirzepatide
- Outcome
- DecreaseHbA1c change from baseline at week 40
- Study
n = 475
- Comparator
- Volume-matched placebo added to titrated insulin glargine
- Analysis
- Primary
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- 5 mg, 10 mg or 15 mg once weekly (started at 2.5 mg/week, escalated by 2.5 mg every 4 weeks) · subcutaneous · 40 weeksAs given in this study (human).
Measurements
- HbA1c reduction from baseline at week 40
- 2.4%
- tirzepatide 10 mg
- HbA1c reduction from baseline at week 40
- 2.34%
- tirzepatide 15 mg
- HbA1c reduction from baseline at week 40
- 0.86%
- placebo
- HbA1c difference vs placebo (reduction)
- 1.53%
- tirzepatide 10 mg
- HbA1c difference vs placebo (reduction)
- 1.47%
- tirzepatide 15 mg
Source sentences
At week 40, mean HbA1c change from baseline was -2.40% with 10-mg tirzepatide and -2.34% with 15-mg tirzepatide vs -0.86% with placebo (10 mg: difference vs placebo, -1.53% [97.5% CI, -1.80% to -1.27%]; 15 mg: difference vs placebo, -1.47% [97.5% CI, -1.75% to -1.20%]; P < .001 for both).
3 context sentences(design, population, supporting numbers)
Mean HbA1c change from baseline was -2.11% with 5-mg tirzepatide (difference vs placebo, -1.24% [95% CI, -1.48% to -1.01%]; P < .001]).
in 475 adults with type 2 diabetes and inadequate glycemic control while treated with once-daily insulin glargine with or without metformin
Patients were randomized in a 1:1:1:1 ratio to receive once-weekly subcutaneous injections of 5-mg (n = 116), 10-mg (n = 119), or 15-mg (n = 120) tirzepatide or volume-matched placebo (n = 120) over 40 weeks.